Treatment of Autoimmune Disease by Intense Immunosuppressive Conditioning and Autologous Hematopoietic Stem Cell Transplantation

Richard K. Burt, Ann Traynor, Richard M. Pope, +17

Blood

Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial)

Hung‐Fat Tse, S. Thambar, Yok‐Lam Kwong, +15

European Heart Journal

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

Timothy P. Hughes, Susan Branford, Deborah L. White, +22

Blood

Bone marrow transplants for paroxysmal nocturnal haemoglobinuria

Radovan Sašo, J. C. W. Marsh, Lidija Čevreska, +7

British Journal of Haematology

ImmunohematologyImmunologyTransplantation MedicinePnh PatientsAplastic Anemia +14

T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin’s lymphoma: clinical and molecular follow-up

Mark Juckett, Philip Rowlings, Martin J. Hessner, +10

Bone Marrow Transplantation

Lymphoid NeoplasiaCell TherapyTransplantationMarrow TransplantationMedicine +7

Effect of T cell subset dose on outcome of T cell-depleted bone marrow transplantation

Y Kawanishi, Jakob Passweg, Philip Rowlings, +10

Bone Marrow Transplantation

Cell TherapyTransplantationMarrow TransplantationBone Marrow FailureStem Cell Transplantation +6

Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions

Rajat Kumar, Fumihiko Kimura, Kwang Woo Ahn, +30

Biology of Blood and Marrow Transplantation

Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report from The Center For International Blood & Marrow Transplant Research (CIBMTR)

Hillard M. Lazarus, Jeanette Carreras, Christian Boudreau, +24

Biology of Blood and Marrow Transplantation

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Meletios Α. Dimopoulos, Paul G. Richardson, Nizar J. Bahlis, +272

The Lancet Haematology

Hematological MalignancyOncologyTransplantationHematologyClinical Trials +6

Safety of Catheter-Based Intramyocardial Autologous Bone Marrow Cells Implantation for Therapeutic Angiogenesis

Hung‐Fat Tse, S. Thambar, Yok‐Lam Kwong, +8

The American Journal of Cardiology

Tissue EngineeringRegenerative MedicineCell TherapyEngineeringStem Cells +9